Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.30 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7336615 | 0.80 | PLA2G7 (0.49) | PLA2G7CHRM3 | |
| SCHEMBL5148891 | 0.80 | PLA2G7 (0.49) | PLA2G7CHRM3 | |
| SCHEMBL2714244 | 0.80 | PLA2G7 (0.49) | PLA2G7CHRM3 | |
| SCHEMBL2185862 | 0.77 | PLA2G7 (0.47) | PLA2G7CHRM3ALDH1A1KDM4ELMNA | |
| SCHEMBL13293918 | 0.77 | CHRM3 (0.56) | PLA2G7KMT2ACHRM3MEN1POLB | |
| SCHEMBL14734296 | 0.77 | PLA2G7 (0.45) | PLA2G7CHRM3KDM4ELMNAPOLB | |
| SCHEMBL2714868 | 0.76 | KMT2A (0.32) | PLA2G7KMT2A | |
| SCHEMBL6113637 | 0.75 | PLA2G7 (0.43) | PLA2G7CHRM3POLBBLM | |
| SCHEMBL2713645 | 0.75 | PLA2G7 (0.44) | PLA2G7POLB | |
| Acetic Acid SCHEMBL3243807 | 0.73 | CHRM3 (0.49) | PLA2G7CHRM3MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9248117-B2 | Substituted N,N-dihaloamines as antimicrobials | NOVABAY PHARMACEUTICALS, INC. (US) | 2016-02-02 | — | — | US | disclosed |
| US-9248117-B2 | Substituted N,N-dihaloamines as antimicrobials | NOVABAY PHARMACEUTICALS, INC. (US) | 2016-02-02 | — | — | US | disclosed |
| US-9248117-B2 | Substituted N,N-dihaloamines as antimicrobials | NOVABAY PHARMACEUTICALS, INC. (US) | 2016-02-02 | — | — | US | disclosed |
| EP-2629607-A2 | ANTIMICROBIAL POLYETHER AND POLYOL COMPOUNDS | NovaBay Pharmaceuticals, Inc. (US) | 2013-08-28 | — | — | EP | disclosed |
| US-20120129793-A1 | Antimicrobial Polyether and Polyol Compounds | NOVABAY PHARMACEUTICALS, INC. | 2012-05-24 | — | — | US | disclosed |
| US-20120129793-A1 | Antimicrobial Polyether and Polyol Compounds | NOVABAY PHARMACEUTICALS, INC. | 2012-05-24 | — | — | US | disclosed |
| US-20120129793-A1 | Antimicrobial Polyether and Polyol Compounds | NOVABAY PHARMACEUTICALS, INC. | 2012-05-24 | — | — | US | disclosed |
| WO-2012054521-A2 | ANTIMICROBIAL POLYETHER AND POLYOL COMPOUNDS | NOVABAY PHARMACEUTICLAS, INC. (US) | 2012-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120129793-A1 | Antimicrobial Polyether and Polyol Compounds | POLR1C, DPM1, PRF1 | PLA2G7 2350/4885KMT2A 4521/4885CHRM3 4790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.